Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer

Purpose: This study was undertaken to determine the activity and toxicity of dose-intensive weekly chemotherapy (cisplatin, vincristine, doxorubicin, and etoposide [CODE] regimen) for previous treated, recurrent small-cell lung cancer (SCLC). Patients and Methods: The 17 patients with relapsed study were to receive intensive weekly chemotherapy with the CODE regimen, All 17 patients held been heavily pretreated with some form of cisplatin-based combination chemotherapy. Six patients had received previous chemotherapy with CODE and one patient with cisplatin and etoposide (PE) as induction therapy. Nine patients had been treated with concurrent or sequential PE plus thoracic irradiation (TRT), The median time off chemotherapy war 6.7 months (range, 3.3 to 72), patients were treated with 9 weeks of the CODE regimen, Response, survival, and toxicity data were noted. Results: All 17 patients were assessable far response, survival, and toxicity. Fifteen of 17 patients (88.2%) had an objective response, with five complete responses (CRs; 29%) and 10 partial responses (PRs; 58.8%). The median durations of response and survival were 156 days and 245 days, respectively. Myelosuppression was significant, with 76% of patients developing grade 4 leukopenia, No treatment-related death was observed, Conclusion: The CODE regimen is highly active in the treatment of relapsed SCLC with an encouraging survival outcome. (C) 1997 by American Society of Clinical Oncology.